Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

8 year–15 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology

Chicago, Illinois, 60612, United States

About this study

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

African-American race, born in the U.S.
Age 8-15 years
Clinical diagnosis of asthma
Subject is able to understand and follow verbal instructions in English

Exclusion criteria

Asthma exacerbation in the 4 weeks preceding the research visit
Oral/IV steroid use in the 4 weeks preceding the research visit
Upper or lower respiratory tract infection in the 4 weeks preceding the research visit
Antibiotic use in the 4 weeks preceding the research visit
Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing)
Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Treatment and study plan

Primary outcomes

Interleukin-13 from phytohemagglutinin activated peripheral blood mononuclear cells

Time frame: 7 months (from the start to completion of study. The blood was drawn at the one and only visit for each subject)

Secondary outcomes

Lung function measured by percent predicted forced expiratory volume in the first second (FEV1%)

Time frame: 7 months (from the start to completion of study, but FEV1% was measured at the one and only visit for each subject)

Sponsors and collaborators

Lead sponsor

Rush University Medical Center

Other

Registry information

Official study title

Cytokine Production in Children With Asthma.

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Aug 28, 2009
Registry last updated: Aug 28, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed